<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34967083</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>990</StartPage><EndPage>999</EndPage><MedlinePgn>990-999</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15237</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">The aim was to evaluate urinary neopterin, a marker of pro-inflammatory state, as a potential biomarker of disease prognosis and progression in amyotrophic lateral sclerosis (ALS); and to compare its utility to urinary neurotrophin receptor p75 extracellular domain (p75<sup>ECD</sup> ).</AbstractText><AbstractText Label="METHODS">This was an observational study including 21 healthy controls and 46 people with ALS, 29 of whom were sampled longitudinally. Neopterin and p75<sup>ECD</sup> were measured using enzyme-linked immunoassays. Baseline and longitudinal changes in clinical measures, neopterin and urinary p75<sup>ECD</sup> were examined, and prognostic utility was explored by survival analysis.</AbstractText><AbstractText Label="RESULTS">At baseline, urinary neopterin was higher in ALS compared to controls (181.7&#xa0;&#xb1;&#xa0;78.9&#xa0;&#x3bc;mol/mol creatinine vs. 120.4&#xa0;&#xb1;&#xa0;60.8&#xa0;&#x3bc;mol/mol creatinine, p&#xa0;=&#xa0;0.002, Welch's t test) and correlated with the Revised ALS Functional Rating Scale (r&#xa0;=&#xa0;-0.36, p&#xa0;=&#xa0;0.01). Combining previously published urinary p75<sup>ECD</sup> results from 22 ALS patients with a further 24 ALS patients, baseline urinary p75<sup>ECD</sup> was also higher compared to healthy controls (6.0&#xa0;&#xb1;&#xa0;2.7 vs. 3.2&#xa0;&#xb1;&#xa0;1.0&#xa0;ng/mg creatinine, p&#xa0;&lt;&#xa0;0.0001) and correlated with the Revised ALS Functional Rating Scale (r&#xa0;=&#xa0;-0.36, p&#xa0;=&#xa0;0.01). Urinary neopterin and p75<sup>ECD</sup> correlated with each other at baseline (r&#xa0;=&#xa0;0.38, p&#xa0;=&#xa0;0.009). In longitudinal analysis, urinary neopterin increased on average (&#xb1;SE) by 6.8&#xa0;&#xb1;&#xa0;1.1&#xa0;&#xb5;mol/mol creatinine per month (p&#xa0;&lt;&#xa0;0.0001) and p75<sup>ECD</sup> by 0.19&#xa0;&#xb1;&#xa0;0.02&#xa0;ng/mg creatinine per month (p&#xa0;&lt;&#xa0;0.0001) from diagnosis in 29 ALS patients.</AbstractText><AbstractText Label="CONCLUSION">Urinary neopterin holds promise as marker of disease progression in ALS and is worthy of future evaluation for its potential to predict response to anti-inflammatory therapies.</AbstractText><CopyrightInformation>&#xa9; 2021 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shepheard</LastName><ForeName>Stephanie R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-2358-7348</Identifier><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karnaros</LastName><ForeName>Vassilios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benyamin</LastName><ForeName>Beben</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5608-2293</Identifier><AffiliationInfo><Affiliation>Australian Centre for Precision Health and Allied Health and Human Performance Unit, University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>David W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-6319-7574</Identifier><AffiliationInfo><Affiliation>Neurology Department and MND Clinic, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubowsky</LastName><ForeName>Megan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0146-4814</Identifier><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chataway</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0254-8099</Identifier><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuromuscular Department, Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Mary-Louise</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-3482-8741</Identifier><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MALASPINA/APR13/817-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS107027</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>670-65-5</RegistryNumber><NameOfSubstance UI="D019798">Neopterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019798" MajorTopicYN="N">Neopterin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">disease progression</Keyword><Keyword MajorTopicYN="N">pharmacodynamic</Keyword><Keyword MajorTopicYN="N">proinflammatory</Keyword></KeywordList><CoiStatement><b>Conflicts of Interest</b>: Research Assoc. Professor J. Wuu reports grants from the National Institutes of Health and Target ALS during the conduct of the study. Professor M. Benatar reports grants from National Institutes of Health, the ALS Association, the Muscular Dystrophy Association, the Centers for Disease Control and Prevention, the Department of Defense, and Target ALS during the conduct of the study; personal fees from Roche, Biogen, Jazz Pharmaceuticals, and AveXis outside the submitted work. In addition, Dr. Benatar has a provisional patent entitled &#x2018;Determining Onset of Amyotrophic Lateral Sclerosis&#x2019;. Dr. Benatar also serves as a site investigator on clinical trials funded by Biogen and Orphazyme, and as the global coordinating investigator for Orphazyme&#x2019;s trial of Arimoclomol in ALS. Professor A. Malaspina reports grants from the ALS Association, MND Association UK, Wellcome Trust UK, NIHR UK, Barts and The London Charities UK. He has acted as consultant and received personal fees from Roche and Pfizer. He has a joint provisional patent entitled &#x2018;Determining Onset of Amyotrophic Lateral Sclerosis&#x2019; with Dr Benatar. Assoc Professor M-L Rogers reports grants from MND Research Australia, FightMND, the ALS Association, Target ALS and National Institutes of Health. In addition, Assoc Prof Rogers, Dr Shepheard and Assoc Prof Chataway have a provisional patent entitled &#x201c;Antibody against ALS Biomarker&#x201d;.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>30</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34967083</ArticleId><ArticleId IdType="mid">NIHMS1767701</ArticleId><ArticleId IdType="pmc">PMC8901536</ArticleId><ArticleId IdType="doi">10.1111/ene.15237</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benatar M, Boylan K, Jeromin A, et al. ALS biomarkers for therapy development: State of the field and future directions. Muscle &amp; Nerve 2016;53:169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718795</ArticleId><ArticleId IdType="pubmed">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Berry JD, Windebank A, et al. Addressing heterogeneity in amyotrophic lateral sclerosis Clinical Trials. Muscle Nerve 2020;62:156&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology 2017;88:1137&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, Rowe DB, Kiernan MC, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotrophic lateral sclerosis and frontotemporal degeneration 2019;63:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 2020;95:e59&#x2013;e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2020;383:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese AM, Sharma A, Mishra P, et al. Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clinical proteomics 2013;10:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4220794</ArticleId><ArticleId IdType="pubmed">24295388</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Thezenas ML, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol 2018;83:258&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Verde F, Fang L, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of neurology, neurosurgery, and psychiatry 2018;89:239&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese AM, Ghosh M, Bhagat SK, et al. Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammation. J Neuroinflammation 2020;17:232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412641</ArticleId><ArticleId IdType="pubmed">32762702</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu L, An J, Kovalik T, Gendron T, Petrucelli L, Bowser R. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry 2020;91:350&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147184</ArticleId><ArticleId IdType="pubmed">31937582</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. International Immunology 2015;27:117&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NO, Schurr C, Heuvel FO, et al.
NF-&#x3ba;B activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. The EMBO Journal
2018;37 (e98697):https://www.embopress.org/doi/full/10.15252/embj.201798697</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798697</ArticleId><ArticleId IdType="pmc">PMC6092622</ArticleId><ArticleId IdType="pubmed">29875132</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 2012;237:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Henkel JS, et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010;58:231&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784168</ArticleId><ArticleId IdType="pubmed">19672969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007;10:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, Van Deerlin VM, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. Plos One 2012;7:e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurol 2017;74:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2015;2:e100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Lyon MS, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune-modulating therapies. Muscle Nerve 2019;59:23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">29979478</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2019;90:1338&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2020;7:1103&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gschwandtner M, Derler R, Midwood KS. More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis. Front Immunol 2019;10:2759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6923224</ArticleId><ArticleId IdType="pubmed">31921102</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. Journal of clinical pharmacy and therapeutics 2001;26:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679022</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero-Luis M, Fernandez-Urena S, Jordan I, et al. Cerebrospinal fluid neopterin analysis in neuropediatric patients: establishment of a new cut off-value for the identification of inflammatory-immune mediated processes. Plos One 2013;8:e83237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867431</ArticleId><ArticleId IdType="pubmed">24367586</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins RdP, Ghisoni K, Lim CK, Aguiar AS, Guillemin GJ, Latini A. Neopterin preconditioning prevents inflammasome activation in mammalian astrocytes. Free Radical Biology and Medicine 2018;115:371 &#x2013; 382.</Citation><ArticleIdList><ArticleId IdType="pubmed">29198726</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2187425</ArticleId><ArticleId IdType="pubmed">6429267</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero-Luis M, Casas-Alba D, Orellana G, et al. Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases. Sci Rep 2020;10:18291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7588460</ArticleId><ArticleId IdType="pubmed">33106568</ArticleId></ArticleIdList></Reference><Reference><Citation>Westarp ME, Fuchs D, Bartmann P, et al. Amyotrophic lateral sclerosis an enigmatic disease with B-cellular and anti-retroviral immune responses. The European journal of medicine 1993;2:327&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">8252177</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Gerardi F, et al. Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis. Journal of neurology 2020;7:639.</Citation><ArticleIdList><ArticleId IdType="pubmed">32638112</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000. Dec;1(5):293&#x2013;9. doi: 10.1080/146608200300079536. PMID: 11464847</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2020495</ArticleId><ArticleId IdType="pubmed">17941714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mischak H, Kolch W, Aivaliotis M, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 2010;4:464&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064949</ArticleId><ArticleId IdType="pubmed">21137064</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann J, Thiemann F, Gerstner L, et al. Evaluation of a new simple and rapid enzyme-linked immunosorbent assay kit for neopterin determination. Clin Chem Lab Med 2000;38:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">10928656</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson SJ, Schatteman GC, Gown AM, Bothwell M. A monoclonal antibody against nerve growth factor receptor. Immunohistochemical analysis of normal and neoplastic human tissue. Am J Clin Pathol 1989;92:415&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">2552791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikheev MI, Lowry LK. WHO global project on biological monitoring of chemical exposure at the workplace. Int Arch Occup Environ Health 1996;68:387&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">8891772</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SG, Krame BS. Peirce, Youden, and Receiver Operating Characteristic Curves. The American Statistician 2007;61:343&#x2013;346.</Citation></Reference><Reference><Citation>Werner ER, Bichler A, Daxenbichler G, et al. Determination of neopterin in serum and urine. Clinical chemistry 1987;33:62&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Kordower JH. Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer disease. P Natl Acad Sci USA 1992;89:569&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48280</ArticleId><ArticleId IdType="pubmed">1309947</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Zhao W, Thonhoff JR, Wang J, Wen S, Appel SH. Increased activation ability of monocytes from ALS patients. Exp Neurol 2020;328:113259.</Citation><ArticleIdList><ArticleId IdType="pubmed">32105709</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts K, Zeineddine R, Corcoran L, Li W, Campbell IL, Yerbury JJ. Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype. Glia 2013;61:409&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">23281114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Lindberg RL, Regeniter A, et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol 2009;16:771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliardini V, Pagliardini S, Corrado L, et al. Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J Neurol Sci 2015;348:245&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">25563799</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav 2017;7:e00637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep 2017;7:9094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;3:e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahsen BF, Gray E, Thompson AG, et al. Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers. Nat Rev Neurol 2021;17:333&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">33927394</ArticleId></ArticleIdList></Reference><Reference><Citation>Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002;3:175&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">12003349</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackman RP, Utter GH, Heitman JW, et al. Effects of blood sample age at time of separation on measured cytokine concentrations in human plasma. Clin Vaccine Immunol 2011;18:318&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067358</ArticleId><ArticleId IdType="pubmed">21159926</ArticleId></ArticleIdList></Reference><Reference><Citation>Valaperti A, Bezel P, Vonow-Eisenring M, Franzen D, Steiner UC. Variability of cytokine concentration in whole blood serum and bronchoalveolar lavage over time. Cytokine 2019;123:154768.</Citation><ArticleIdList><ArticleId IdType="pubmed">31276936</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida Y, Une F, Utatsu Y, et al. Adenosine and neopterin levels in cerebrospinal fluid of patients with neurological disorders. Internal medicine (Tokyo, Japan) 1999;38:133&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">10225668</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton C, Shi H, Ma Y. Development of a high-performance liquid chromatography - Tandem mass spectrometry urinary pterinomics workflow. Analytica chimica acta 2016;927:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">27237839</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>